BDX · NYSE · STOCK
Becton Dickinson (BDX) Stock Analysis
$182.25
52W $127.59 – $187.35
53/100
$50.53B
55.2
0.26
Is BDX Bullish or Bearish?
Mixed.
Innellis AI committee rates Becton Dickinson (BDX) Watch with a composite score of 53/100
, based on 6 analysts with 33% agreement.
Last updated August 18, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.41 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.59 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 53.2 is expensive by classic value standards — Value
- ROE of only 3.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -2.6% YoY -- this is not a growth story right now — Growth
- EPS declining -40.4% YoY despite any revenue growth — Growth
- RSI at 82 is in overbought territory — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 18, 2026
Overall Committee Score
53/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 94%
of 192 Healthcare peers
Value Analyst
bearish
35
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 53.2 is expensive by classic value standards
Growth Analyst
neutral
50
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 3 consecutive earnings beats -- consistent execution
− Revenue declining -2.6% YoY -- this is not a growth story right now
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 82 is in overbought territory
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 25.7% signals elevated volatility
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 52.6 to 52.6.
Comparing 2026-08-17 to 2026-08-18 (1 day apart).
Technical Analysis
RSI (14)
81.7
Overbought
MACD Histogram
1.283
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$178.14
Resistance
$195.24
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$178.25
Above
EMA 21
$170.69
Above
EMA 50
$162.39
Above
EMA 200
$168.52
Above
Fundamental Analysis
Valuation
64
Growth
69
Profitability
38
Financial Health
48
Cash Flow
70
Valuation
P/E Ratio
55.2×
P/B Ratio
2.06×
PEG Ratio
-1.37
Dividend Yield
2.04%
52W High
$187.35
52W Low
$127.59
Quality & Growth
ROE
660.9%
ROA
303.3%
Gross Margin
4612.0%
Operating Margin
982.8%
Revenue Growth YoY
—
Debt / Equity
0.69
AI Fundamental Assessment
P/E ratio of 55.2 (rich relative to a 15-40x range); Price-to-book of 2.1x; PEG ratio of -1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.6%; Return on assets of 3.0%; Net margin of 4.5%; Gross margin of 46.1%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.69; Free cash flow per share is positive (9.48); Most recent quarter beat estimates by 1.8%; 3 consecutive earnings beats; EPS growth accelerating (-0.3% -> +11.4% QoQ); Average YoY EPS growth of -12.2%; Analyst estimates rising over recent quarters
Get the Full BDX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →